Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction

被引:242
作者
Stanek, B [1 ]
Frey, B
Hülsmann, M
Berger, R
Sturm, B
Strametz-Juranek, J
Bergler-Klein, J
Moser, P
Bojic, A
Hartter, E
Pacher, R
机构
[1] Univ Vienna, Dept Cardiol, Ludwig Boltzmann Inst Expt Endocrinol, A-1090 Vienna, Austria
[2] Univ Vienna, Ludwig Boltzmann Inst Cardiovasc Res, A-1090 Vienna, Austria
关键词
D O I
10.1016/S0735-1097(01)01383-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The study assessed the relative predictive potency of neurohumoral factors in patients with advanced left ventricular (LV) dysfunction during neurahumoral blocking therapy. Background The course of heart failure is characterised by progressive LV deterioration assoc-fated with an increase in cardiac (natriuretic peptides) and predominantly extracardiac (norepinephrine, big endothelin [big ET]) hormone plasma levels. Methods Plasma hormones were measured at baseline and months 3, 6, 12 and 24 in 91 patients with heart failure (left ventricular ejection fraction [LVEF] <25%) receiving 40 mg enalapril/day and double-blind atenolol (50 to 100 mg/day) or placebo. After the double-blind study phase, patients were followed up to four years. Stepwise multivariate regression analyses were performed with 10 variables (age, etiology, LVEF, symptom glass, atenolol/placebo, norepinephrine, big ET, log aminoterminal atrial natriuretic peptide, log aminoterminal B-type natriuretic peptide [N-BNP] and log B-type natriuretic peptide [BNP]). During the study, the last values prior to patient death were used, and in survivors the last hormone level, New York Heart Association class and LVEF at month 24 were used. Results Thirty-one patients died From a cardiovascular cause during follow-up. At baseline, log BNP plasma level (x(2) = 13.9, p = 0.0002), treatment allocation (x(2) = 9.5, p = 0.002) and LVEF (x(2) = 5.6, p = 0.017) were independently related to mortality. During the study, log BNP plasma level (x(2) = 21.3, p = 0.0001) remained the strongest predictive marker, with LVEF (x(2) = 11.2, = 0.0008) log N-BNP plasma level (x(2) = 8.9, p = 0.0027) and treatment allocation (x(2) = 6.4 p = 0.0109) providing additional independent information. Conclusions In patients with advanced LV dysfunction receiving high-dose angiotensin-converting enzyme inhibitors and beta-blocker therapy BNP and N-BNP plasma Levels are bath independently related to mortally. This observation highlights the importance of these hormones and implies drat they will likely emerge as a very useful blood test for detection of the progression of heart failure, even in the face of neurohumoral blocking thcrapy. (J Am Cell Cardiol 2001;38:436-42) (C) 2001 by the American College of Cardiology.
引用
收藏
页码:436 / 442
页数:7
相关论文
共 28 条
[1]   BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria [J].
Bruneau, BG ;
Piazza, LA ;
de Bold, AJ .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1997, 273 (06) :H2678-H2686
[2]   Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators [J].
Daggubati, S ;
Parks, JR ;
Overton, RM ;
Cintron, G ;
Schocken, DD ;
Vesely, DL .
CARDIOVASCULAR RESEARCH, 1997, 36 (02) :246-255
[3]   Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction [J].
Davidson, NC ;
Naas, AA ;
Hanson, JK ;
Kennedy, NSJ ;
Coutie, WJ ;
Struthers, AD .
AMERICAN JOURNAL OF CARDIOLOGY, 1996, 77 (10) :828-831
[4]   PLASMA PROATRIAL NATRIURETIC FACTOR IS PREDICTIVE OF CLINICAL STATUS IN PATIENTS WITH CONGESTIVE-HEART-FAILURE [J].
DICKSTEIN, K ;
LARSEN, AI ;
BONARJEE, V ;
THORESEN, M ;
AARSLAND, T ;
HALL, C .
AMERICAN JOURNAL OF CARDIOLOGY, 1995, 76 (10) :679-683
[5]   The effects of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure [J].
Dickstein, K ;
Manhenke, C ;
Aarsland, T ;
McNay, J ;
Wiltse, C ;
Wright, T .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2000, 75 (2-3) :167-176
[6]   EFFECTS OF BUCINDOLOL IN HEART-FAILURE [J].
EICHHORN, EJ .
AMERICAN JOURNAL OF CARDIOLOGY, 1993, 71 (09) :C65-C70
[7]   EFFECT OF METOPROLOL ON MYOCARDIAL-FUNCTION AND ENERGETICS IN PATIENTS WITH NONISCHEMIC DILATED CARDIOMYOPATHY - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY [J].
EICHHORN, EJ ;
HEESCH, CM ;
BARNETT, JH ;
ALVAREZ, LG ;
FASS, SM ;
GRAYBURN, PA ;
HATFIELD, BA ;
MARCOUX, LG ;
MALLOY, CR .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, 24 (05) :1310-1320
[8]   Prognostic value of hemodynamic vs big endothelin measurements during long-term IV therapy in advanced heart failure patients [J].
Frey, B ;
Pacher, R ;
Locker, G ;
Bojic, A ;
Hartter, E ;
Woloszczuk, W ;
Stanek, B .
CHEST, 2000, 117 (06) :1713-1719
[9]  
Garlichs CD, 1999, EUR J CLIN INVEST, V29, P12
[10]   Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart [J].
Gilbert, EM ;
Abraham, WT ;
Olsen, S ;
Hattler, B ;
White, M ;
Mealy, P ;
Larrabee, P ;
Bristow, MR .
CIRCULATION, 1996, 94 (11) :2817-2825